SAB Change To Inventory from 2010 to 2026
| SABS Stock | USD 4.17 0.19 4.77% |
Change To Inventory | First Reported 2010-12-31 | Previous Quarter 436.4 K | Current Value 387.9 K | Quarterly Volatility 25.6 K |
Check SAB Biotherapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among SAB Biotherapeutics' main balance sheet or income statement drivers, such as Net Interest Income of 1.2 M, Interest Income of 1.6 M or Depreciation And Amortization of 5.8 M, as well as many indicators such as Price To Sales Ratio of 34.17, Dividend Yield of 0.0 or PTB Ratio of 1.28. SAB financial statements analysis is a perfect complement when working with SAB Biotherapeutics Valuation or Volatility modules.
SAB | Change To Inventory | Build AI portfolio with SAB Stock |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for SAB Stock Analysis
When running SAB Biotherapeutics' price analysis, check to measure SAB Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy SAB Biotherapeutics is operating at the current time. Most of SAB Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of SAB Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move SAB Biotherapeutics' price. Additionally, you may evaluate how the addition of SAB Biotherapeutics to your portfolios can decrease your overall portfolio volatility.